Major Indexes

My Watchlist Items

      No Watchlist
Array ( [0] => stdClass Object ( [symbol] => INBX [price] => 17.33 [beta] => 0 [volAvg] => 127456 [mktCap] => 655261184 [lastDiv] => 0 [range] => 14.27-50.97 [changes] => 0.36 [companyName] => Inhibrx, Inc. [currency] => USD [cik] => 0001739614 [isin] => US45720L1070 [cusip] => 45720L107 [exchange] => Nasdaq Global Select [exchangeShortName] => NASDAQ [industry] => Biotechnology [website] => http://www.inhibrx.com [description] => Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California. [ceo] => Mr. Mark Paul Lappe [sector] => Healthcare [country] => US [fullTimeEmployees] => 84 [phone] => 858-795-4220 [address] => 11025 North Torrey Pines Road [city] => La Jolla [state] => CA [zip] => [dcfDiff] => [dcf] => 0 [image] => https://financialmodelingprep.com/image-stock/INBX.png [ipoDate] => 2020-08-19 [defaultImage] => [isEtf] => [isActivelyTrading] => 1 ) )
Inhibrx, Inc. (INBX)
   17.33   0.36(+2.12%)
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
TitleNamePayCurrency PayGenderYear BornTitle Since
Executive Vice President of Clinical Operations Mr. Jeffrey J. Jensen N/A USD male N/A N/A
Executive Vice President of Translational Research Ms. Analeah Heidt Ph.D. N/A USD female N/A N/A
Vice President, Assistant Sec. & Gen. Counsel Ms. Leah Pollema J.D. N/A USD female N/A N/A
Executive Vice President & Chief Technical Operations Officer Dr. Ashraf Amanullah N/A USD N/A N/A
Chief Financial Officer & Sec. Ms. Kelly Devine Deck B.S., CPA, M.S. N/A USD female N/A N/A
Founder & Executive Vice President of Early Research Mr. Quinn L. Deveraux N/A USD male N/A N/A
Chief Medical Officer & Executive Vice President Dr. Klaus W. Wagner 518000 USD 1972 N/A
Founder, Chief Scientific Officer, Executive Vice President of Corporation Strategy & Director Dr. Brendan P. Eckelman 679000 USD 1979 N/A
Founder, Chairman, Pres & Chief Executive Officer Mr. Mark Paul Lappe 864000 USD male 1967 N/A
HolderSharesDate ReportedChange
TYBOURNE CAPITAL MANAGEMENT (HK) LTD 1100000 31 March, 2021 0
RA CAPITAL MANAGEMENT, L.P. 2129003 31 December, 2020 0
FMR LLC 1597827 31 December, 2020 -147199
ARROWMARK COLORADO HOLDINGS LLC 1556319 31 December, 2020 1056593
CAPITAL WORLD INVESTORS 1200000 31 December, 2020 194954
FARALLON CAPITAL MANAGEMENT LLC 510000 31 December, 2020 115000
BLACKROCK INC. 495032 31 December, 2020 397934
VANGUARD GROUP INC 380849 31 December, 2020 350849
SOLEUS CAPITAL MANAGEMENT, L.P. 213807 31 December, 2020 -192693
GEODE CAPITAL MANAGEMENT, LLC 149550 31 December, 2020 129465
STATE STREET CORP 132527 31 December, 2020 132527
VICTORY CAPITAL MANAGEMENT INC 104200 31 December, 2020 -16230
NORTHERN TRUST CORP 99200 31 December, 2020 99200
MILLENNIUM MANAGEMENT LLC 72304 31 December, 2020 4628
PLATINUM INVESTMENT MANAGEMENT LTD 60105 31 December, 2020 -14895
JANUS HENDERSON GROUP PLC 53213 31 December, 2020 53213
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 49130 31 December, 2020 49130
SPHERA FUNDS MANAGEMENT LTD. 43182 31 December, 2020 43182
DARWIN GLOBAL MANAGEMENT, LTD. 36534 31 December, 2020 36534
NUVEEN ASSET MANAGEMENT, LLC 32818 31 December, 2020 32818
PARAMETRIC PORTFOLIO ASSOCIATES LLC 29443 31 December, 2020 -12741
BANK OF NEW YORK MELLON CORP 27816 31 December, 2020 27816
JPMORGAN CHASE & CO 22484 31 December, 2020 22484
SWISS NATIONAL BANK 21300 31 December, 2020 21300
WELLS FARGO & COMPANY/MN 21249 31 December, 2020 14049
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 16275 31 December, 2020 16275
GOLDMAN SACHS GROUP INC 12517 31 December, 2020 -77213
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 12292 31 December, 2020 12292
M&T BANK CORP 11598 31 December, 2020 0
IKARIAN CAPITAL, LLC 8076 31 December, 2020 8076
VIRTUS ETF ADVISERS LLC 7133 31 December, 2020 7133
ATHANOR CAPITAL, LP 6573 31 December, 2020 6573
RHUMBLINE ADVISERS 6490 31 December, 2020 6490
MORGAN STANLEY 6167 31 December, 2020 6167
DEUTSCHE BANK AG\ 5701 31 December, 2020 5701
AMERICAN INTERNATIONAL GROUP, INC. 4725 31 December, 2020 4725
NEW YORK STATE COMMON RETIREMENT FUND 4700 31 December, 2020 4700
METLIFE INVESTMENT MANAGEMENT, LLC 3963 31 December, 2020 3963
BANK OF AMERICA CORP /DE/ 2783 31 December, 2020 -4889
METROPOLITAN LIFE INSURANCE CO/NY 2769 31 December, 2020 2769
STRS OHIO 2000 31 December, 2020 2000
UBS GROUP AG 1926 31 December, 2020 839
ADVISOR GROUP HOLDINGS, INC. 1900 31 December, 2020 0
CITIGROUP INC 1632 31 December, 2020 1632
BANK OF MONTREAL /CAN/ 1274 31 December, 2020 1274
LEGAL & GENERAL GROUP PLC 858 31 December, 2020 858
TOWER RESEARCH CAPITAL LLC (TRC) 774 31 December, 2020 774
AMERITAS INVESTMENT PARTNERS, INC. 681 31 December, 2020 681
GREAT WEST LIFE ASSURANCE CO /CAN/ 662 31 December, 2020 662
VIKING GLOBAL INVESTORS LP 5305866 31 December, 2020 0
ROYAL BANK OF CANADA 576 31 December, 2020 191
SymbolTransaction DateReporting CikSecurities Owned Company CikReporting NameAcquistion Or DispositionForm Type Securities TransactedSecurity NameLink
INBX 17 February, 2021 0001766477 215150 0001739614 Wagner Klaus W. D 4 19559 Common Stock View
INBX 16 February, 2021 0001766433 2572953 0001739614 Eckelman Brendan P. D 4 17000 Common Stock View
INBX 16 February, 2021 0001766477 234709 0001739614 Wagner Klaus W. D 4 156474 Common Stock View
INBX 15 January, 2021 0001366074 145000 0001739614 Lappe Mark A 4 145000 Stock Option (right to buy) View
INBX 15 January, 2021 0001766477 120000 0001739614 Wagner Klaus W. A 4 120000 Stock Option (right to buy) View
INBX 15 January, 2021 0001766433 40000 0001739614 Eckelman Brendan P. A 4 40000 Stock Option (right to buy) View
INBX 15 January, 2021 0001819427 70000 0001739614 Deck Kelly A 4 70000 Stock Option (right to buy) View
INBX 28 December, 2020 0001366074 2590252 0001739614 Lappe Mark D 4 500000 Common Stock View
INBX 28 December, 2020 0001366074 500000 0001739614 Lappe Mark A 4 500000 Common Stock View
INBX 4 December, 2020 0001766433 80000 0001739614 Eckelman Brendan P. A 4 80000 Common Stock View
INBX 4 December, 2020 0001766433 2589953 0001739614 Eckelman Brendan P. D 4 160000 Common Stock View
INBX 26 August, 2020 0001103804 1327307 0001739614 VIKING GLOBAL INVESTORS LP A 4 80219 Common Stock View
INBX 26 August, 2020 0001103804 1427307 0001739614 VIKING GLOBAL INVESTORS LP A 4 100000 Common Stock View
INBX 25 August, 2020 0001103804 1247088 0001739614 VIKING GLOBAL INVESTORS LP A 4 70479 Common Stock View
INBX 25 August, 2020 0001103804 1176609 0001739614 VIKING GLOBAL INVESTORS LP A 4 14825 Common Stock View
INBX 24 August, 2020 0001103804 1161784 0001739614 VIKING GLOBAL INVESTORS LP A 4 46161 Common Stock View
INBX 21 August, 2020 0001202094 17259 0001739614 MANHARD KIMBERLY A 4 17259 Common Stock View
INBX 21 August, 2020 0001346824 2129003 0001739614 RA CAPITAL MANAGEMENT, L.P. A 4 2129003 Common Stock View
INBX 21 August, 2020 0001240801 0 0001739614 FORSYTH DOUGLAS D 4 143266 Series Mezzanine 2 Preferred Stock View
INBX 21 August, 2020 0001240801 598257 0001739614 FORSYTH DOUGLAS A 4 82422 Common Stock View
INBX 21 August, 2020 0001346824 0 0001739614 RA CAPITAL MANAGEMENT, L.P. D 4 3700634 Series Mezzanine 2 Preferred Stock View
SymbolDatePeriodDownload XLSX File
INBX 2020 FY Download XLSX File
INBX 2020 Q3 Download XLSX File
INBX 2020 Q4 Download XLSX File

Charts

Company Historical Earnings

DateSymbolEPSEPS EstimatedTimeRevenueRevenue Estimated
13 May, 2021 INBX -0.51 -0.51 bmo 0 0
12 March, 2021 INBX -0.47 -0.47 bmo 2776000 0
19 August, 2020 INBX bmo 13535000 0

Company Profile

Company Name Inhibrx, Inc.
Symbol INBX
Currency USD
Price 17.33
Exchange Name Nasdaq Global Select (NASDAQ)
Industry Biotechnology
CEO Mr. Mark Paul Lappe
Sector Healthcare
Country US
Full Time Employees 84
Phone 858-795-4220
Address 11025 North Torrey Pines Road
City La Jolla
State CA
>